Novartis India Acquires Minipress Brand for ₹1,250 Crore

Novartis India's board has approved the acquisition of the Minipress and Minipres trademarks from Pfizer Inc and Pfizer Products Inc for ₹1,250 crore. The deal includes certain intellectual property rights linked to the brands.

The acquisition was completed simultaneously with the signing of an asset purchase agreement and trademark assignment deeds. Minipress XL, the drug associated with the brand, generates ₹228.6 crore in revenue and has a compound annual growth rate of 6.3 percent over the past four years.

Minipress XL is primarily prescribed for treating hypertension and managing urinary symptoms associated with benign prostatic hyperplasia. The broader category has expanded at a faster CAGR of 9 percent during the same period.

Novartis India stated that the acquisition is not a related-party transaction, and Pfizer Inc and Pfizer Products Inc are unrelated to its promoter, promoter group, or group companies.

Pfizer has announced that it will discontinue the marketing, distribution, and sale of Minipress XL in India from September 7, 2026, following its decision to stop manufacturing the medicine. Pfizer Ltd will receive a lump-sum payment of USD 13.9 million from its US-based parent.

The acquisition comes after Dr Reddy's Laboratories terminated its distribution and promotion agreement with Novartis India for select domestic brands. Dr Reddy's will continue commercializing the covered brands until September 30, 2026.

Novartis India shares were trading 2.9 percent higher at ₹1,683.35 on the BSE, while Pfizer shares were trading 0.8 percent lower at ₹4,572.70 on the NSE.

The acquisition is a significant development in the pharmaceutical industry, with Novartis India expanding its portfolio of brands. The move is expected to have a positive impact on the company's revenue and growth prospects.

In the context of the Indian pharmaceutical market, the acquisition highlights the growing demand for hypertension treatments. The market is expected to continue growing, driven by an increasing prevalence of hypertension and other cardiovascular diseases.

The deal also underscores the importance of intellectual property rights in the pharmaceutical industry. The acquisition of the Minipress and Minipres trademarks will enable Novartis India to strengthen its position in the market and expand its product offerings.

Overall, the acquisition is a strategic move by Novartis India to enhance its portfolio and drive growth. The company's shares have gained around 68 percent in 2026, reflecting the positive sentiment among investors.

The acquisition is expected to have a significant impact on the Indian pharmaceutical industry, with Novartis India emerging as a major player in the market. The company's focus on expanding its portfolio of brands and strengthening its position in the market is expected to drive growth and revenue in the coming years.

In conclusion, the acquisition of the Minipress brand by Novartis India is a significant development in the pharmaceutical industry. The deal highlights the growing demand for hypertension treatments and the importance of intellectual property rights in the industry. The acquisition is expected to have a positive impact on Novartis India's revenue and growth prospects, and the company is well-positioned to emerge as a major player in the Indian pharmaceutical market.